Anti-Fibrinolytic Drugs - Benin

Benin

The projected revenue for the Anti-Fibrinolytic Drugs market in Benin is expected to reach US$0.55m by 2024.
The market is anticipated to demonstrate an annual growth rate (CAGR 2024-2029) of 4.64%, leading to a market volume of US$0.69m by 2029.
In terms of global comparison, United States is expected to generate the highest revenue, amounting to US$9,858.00m in 2024.
The demand for anti-fibrinolytic drugs in Benin is increasing due to a rising prevalence of bleeding disorders.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Fibrinolytic Drugs market in Benin is a rapidly growing market.

Customer preferences: The customers in Benin are increasingly becoming aware of the benefits of Anti-Fibrinolytic Drugs. The rising prevalence of bleeding disorders and the aging population are the major drivers of the market. The demand for these drugs is expected to increase in the coming years due to the rising number of surgeries and trauma cases.

Trends in the market: The Anti-Fibrinolytic Drugs market in Benin is witnessing a significant growth due to the increasing awareness among people about the benefits of these drugs. The market is expected to grow at a steady rate in the coming years due to the rising prevalence of bleeding disorders and the aging population. The increasing number of surgeries and trauma cases is also expected to drive the market growth.

Local special circumstances: Benin is a low-income country with a high burden of communicable diseases. The healthcare infrastructure in the country is underdeveloped, and there is a shortage of healthcare professionals. The government is taking steps to improve the healthcare infrastructure in the country, but progress has been slow. The lack of access to healthcare facilities is a major challenge for the market.

Underlying macroeconomic factors: The economy of Benin is heavily dependent on agriculture, which accounts for more than one-third of the country's GDP. The country is vulnerable to external shocks, such as changes in commodity prices and weather conditions. The government is taking steps to diversify the economy and reduce its dependence on agriculture. The country has made progress in recent years, but there is still a long way to go. The slow economic growth is a major challenge for the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.